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Background: Immunoglobulin A nephropathy (IgAN), an immune-complex-mediated glomerulonephritis defined
immunohistologically by the presence of glomerular IgA deposits, is the most common primary glomerular disease
worldwide and a significant cause of end-stage renal disease. Familial clustering of patients with IgAN suggests a
genetic predisposition.
Methods: In this study, 192 patients with IgAN and 192 normal controls in the Sichuan cohort and 935 patients
with IgAN and 2,103 normal controls in the Beijing cohort were investigated. HLA-DRB1*01–DRB1*10 specificities
were genotyped by the PCR–SSP technique in both cohorts. Based on the HLA-DRB1*04-positive results, the
subtypes of HLA-DRB1*04 were analyzed using sequencing-based typing (SBT) in 291 IgAN cases and 420 matched
controls.
Results: The frequency of HLA-DRB1*04 in the IgAN group was significantly higher than that in the control group
(0.129 vs. 0.092, P= 8.29 × 10-5, odds ratio (OR) =1.381, 95% confidence interval (CI) 1.178–1.619). Other alleles at the
HLA-DRB1 locus were observed with no significant differences between the case and control groups. The dominant
alleles of the HLA-DRB1*04 subtypes were DRB1*0405 in both cohorts. The frequencies of HLA-DRB1*0405 and 0403
were significantly increased in the patients compared to healthy subjects.
Conclusion: HLA-DRB1*04 was significantly associated with primary IgAN in Chinese population. This result implies
that HLA-DRB1 gene plays a major role in primary IgAN.
Keywords: IgA nephropathy, HLA-DRB1, Association studyBackground
Immunoglobulin A nephropathy (IgAN), an immune-
complex-mediated glomerulonephritis defined immunohis-
tologically by the presence of glomerular IgA deposits, is
the most common primary glomerular disease worldwide
and a significant cause of end-stage renal disease [1]. The
pathogenesis of IgAN remains poorly understood, and its
treatment is limited. No consistent infectious or environ-
mental agent has been identified as responsible for the IgA-
antibody response. However, familial aggregation of patients* Correspondence: zliny@yahoo.com; hongzh@bjmu.edu.cn;
scwangli62@163.com
1Center for Human Molecular Biology & Genetics, Sichuan Academy of
Medical Science & Sichuan Provincial People’s Hospital, 32 the First Ring
Road 2 West, Chengdu, Sichuan 617002, China
Full list of author information is available at the end of the article
© 2012 Jiyun et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orwith IgAN suggests that genetic factors contribute to the
development of this disease [2]. Previous genome-wide link-
age studies of multiplex families with IgAN have identified
four loci with significant linkage on 6q22, 2q36, 4q26–31,
and 17q12–22 [3-5]. Unfortunately, to date, no disease-spe-
cific genes linked to the loci have been identified within
the linkage intervals. However, susceptibility to primary
IgAN has been associated with single-nucleotide poly-
morphisms (SNPs) in the E-selectin and L-selectin genes,
HLA-DRA, C1GalT1, and ST6GALNAC2, as well as in the
PIGR gene [6-12]. Moreover, polymorphisms of the ACE
and AGT genes have been associated with progression to
chronic renal failure in patients with primary IgAN [13,14].
The primary function of the human leukocyte antigen
(HLA) system is to regulate the immune response. MHC
Class II molecules are important determinants of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of primary IgAN cases and





Sichuan cohort IgAN patients 192 80 112 32.07 ± 9.77
Controls 192 62 130 63.19 ± 9.14
Beijing cohort IgAN patients 935 498 437 31.18 ± 10.98
Controls 2103 985 1118 49.21 ± 16.02
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alleles for several autoimmune diseases have now been
located in the Class II region. In Caucasian patients with
primary IgAN, a significant increase in the HLA-DQw7
allele frequency has been observed [15]. However, DQ
alleles showed no consistent association with IgAN in
different populations. In British patients, a decreased fre-
quency of DQBI*0201 was observed, in Finnish patients
a decreased frequency of DQB1*0602 was observed, and
in Italian patients, no association between DQ markers
and IgAN was found [16]. Earlier studies have shown
that HLA-DR4 might be associated with IgAN in Japa-
nese [17-19]. However, no association between IgAN
and HLA-A, B, C, DR, and DQ was found in a Chinese
Taiwanese population [20].
On the other hand, in the Italian population with a
family history of primary IgAN, there was an increased
incidence of HLA-DRB1*08 compared to those with
sporadic primary IgAN [21]. In the present study, we
investigated the association between the genetic variants




This study was approved by The Institutional Review
Boards of the Sichuan Provincial People’s Hospital and
Peking University First Hospital, China. All subjects pro-
vided informed consent before participating in the study.
The diagnosis of primary IgAN was confirmed by his-
tological and immunological examinations with renal
biopsy. No clinical or serological evidence of Henoch-
Schonlein purpura, systemic lupus erythematosus, alco-
holic liver disease, or immunological diseases was found
in any of the patients with primary IgAN. Healthy sub-
jects were healthy volunteers with no history of renal
disorder. These subjects were confirmed as being
healthy by detailed clinical and laboratory examinations,
such as blood pressure, urinary protein, creatinine, and
urinalysis with occult blood tests. There was no familial
history of primary IgAN in normal controls and cases.
The Sichuan and Beijing cohorts were recruited from
the renal division of Sichuan Provincial People’s Hospital
and the renal division of Peking University First Hospital,
respectively. In total, 192 patients with IgAN and 192
normal controls were recruited for the Sichuan cohort,
and 935 patients with IgAN and 2,103 normal controls
were recruited for the Beijing cohort. Clinical informa-
tion about the cases and controls is listed in Table 1.
HLA-DRB1 genotyping using PCR–SSP
The genotyping for HLA-DRB1 was performed using
PCR–SSP as described previously [22]. The PCR amplifi-
cations were performed at 94°C or 1 min followed by30 cycles, and the amplification conditions were differ-
ent depending on HLA-DRB1*01–DRB1*10 specificities
[22]. The β-actin gene was used as an internal control to
ensure that the enzymatic in vitro DNA amplification
process had worked in each tube.
HLA-DRB1*04 subtypes detected by DNA
sequencing-based typing (SBT)
The HLA-DRB1*04-positive samples, composed of 291
cases and 420 controls, were selected from the Sichuan
cohort and the Beijing cohort by HLA-DRB1*01–
DRB1*10 specificities. The subtypes of HLA-DRB1*04
were further analyzed in the HLA-DRB1*04-positive
samples, as described previously [23]. The following pri-
mers were used to amplify exon 2 of the HLA-DRB1
gene: forward, 5′- CAggAAACAgCTATgACCTgAgACg-
CACgTTTCTTggAgCAggTTAAAC-3′; and reverse, 5′-
TgTAAAACgACggCCAgTgCTYACCTCgCCKCTgCAC -3′.
The PCR amplification protocols for exon 2 of the HLA-
DRB1 gene were identical and consisted of an initial de-
naturation at 95°C for 15 min, followed by 30 cycles at
95°C for 20 s, 62°Cfor 10 s, and 72°C for 90 s. The PCR
products were purified with the ExoSAP-ITW (USB Cor-
poration) and sequenced employing ABI BigDye chemis-
try (Applied Biosystems). The following primers were
used as sequencing primers: M13F, 5′- CAggAAACAgC-
TATgACC-3′; and M13R, 5′- TgTAAAACgACggCCAgT-
3′. The samples were sequenced using the ABI PRISM
310 Genetic Analyzer (Applied Biosystems). uTYPETM
SBT software was used to process the DNA sequence files
for analysis and HLA-DRB1*04 alleles’ assignment.
Statistical analysis
The frequency distribution of the HLA-DRB1 and HLA-
DRB1*04 subtype alleles in the patient and normal control
groups was compared using a Fisher’s exact test. Stratified
analysis was performed using Cochran-Mantel-Haenszel
method. The IgAN patients were classified into different
subgroups for the purpose of studying the association of
HLA-DRB1*04 alleles with clinical factors of patients by
gender, blood pressure (according to the standard of
hypertension of WHO-ISH in 1999), 24-h content of urine
protein (≥3.5 or <3.5 g/24 h), serum creatinine level
(≤120 or >120 μmol/l), hematuria (positive or negative),
Table 2 A comparison of the frequencies of HLA-DRB1
alleles in primary IgAN patients and healthy controls







P OR 95% CI
DRB1*01 0.023 (9) 0.042 (16) 0.220 0.774 0.572-1.048
DRB1*03 0.055 (21) 0.047 (18) 0.743 1.088 0.769-1.538
DRB1*04 0.143 (55) 0.073 (28) 2.35 × 10-3 1.541 1.130-2.100
DRB1*07 0.057 (22) 0.073 (28) 0.465 0.885 0.685-1.144
DRB1*08 0.060 (23) 0.078 (30) 0.324 0.875 0.683-1.120
DRB1*09 0.158 (61) 0.151 (58) 0.842 1.031 0.844-1.258
DRB1*10 0.031 (12) 0.047 (18) 0.352 0.827 0.612-1.117
DRB1*11–12 0.073 (28) 0.089 (34) 0.508 0.904 0.713-1.147
DRB1*13-14 0.253 (97) 0.268 (103) 0.681 0.961 0.820-1.125
DRB1*15-16 0.091 (35) 0.112 (43) 0.403 0.896 0.724-1.110
OR, odds ratio; CI, confidence interval.
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cerosis (positive or negative). The strength of an associ-
ation with alleles and genotypes was indicated by an
odds ratio (OR) with a 95% confidence interval (CI) and
P value. P value <0.05 was defined as statistically sig-
nificant. SPSS version 13.0 for Windows was used for all
statistical analyses.
Results
The frequencies of HLA-DRB1 alleles in primary IgAN
patients and healthy controls
In the initial study, we tested the frequencies of each
HLA-DRB1 allele in the Sichuan cohort using PCR–SSP.
We found that the frequency of HLA-DRB1*04 in the
IgAN group was significantly higher than that in the
control group (0.143 vs. 0.073, P= 2.35 × 10-3, OR=
1.541, 95% CI, 1.130–2.100) (Table 2). Other alleles at
the HLA-DRB1 locus did not show any differences
between the case and control groups (Table 2). To con-
firm this finding, we genotyped the allele frequencies of
HLA-DRB1*04 in an independent Beijing cohort, com-
posed of 935 patients with IgAN and 2,103 normal con-
trols. In this cohort, the frequency of HLA-DRB1*04 in
the IgAN group was also significantly higher than that in
the healthy control group (0.126 vs. 0.093, P= 2.67× 10-3,
OR= 1.091, 95% CI, 1.028–1.158) (Table 3). When these
two cohorts were combined, the allele frequency ofTable 3 A comparison of the frequencies of HLA-DRB1*04 in
different cohorts
Cohort Case Co
Han Chinese in the Sichuan cohorta 0.143 (55) 0.07
Han Chinese in the Beijing cohorta 0.126 (236) 0.09
Both cohorts combinedb 0.129 (291) 0.09
OR, odds ratio; CI, confidence interval; a Fisher’s exact test, bStratified analysis using
P= 0.057.HLA-DRB1*04 showed a significant difference between
the cases and the controls in the Han Chinese popula-
tion (0.129 vs. 0.092, P= 8.29 × 10-5, OR= 1.381, 95% CI,
1.178–1.619) (Table 3).
Frequency of HLA-DRB1*04 subtypes in primary IgAN
patients and healthy controls
Based on the HLA-DRB1*04-positive results, HLA-
DRB1*04 subtypes were further analysed using SBT in
291 patients with IgAN and 420 matched controls. The
frequency of HLA-DRB1*04 subtypes was successfully
genotyped in 291 patients with IgAN and 405 controls.
In the cohorts studied, the dominant alleles of the HLA-
DRB1*04 subtypes were DRB1*0405. The frequencies of
HLA-DRB1*0405 and 0403 were significantly increased
in the patients compared to healthy subjects (Table 4).
The association of HLA-DRB1*04 alleles and its subtypes
with clinical factors in primary IgAN patients
The IgAN patients were classified into different sub-
groups according to clinical factors. We analysed the
association of HLA-DRB1*04 alleles with clinical factors.
However, our data showed no significant association
between clinical factors and the frequency of the HLA-
DRB1*04 alleles and its subtypes in primary IgAN
patients (Table 5).
Discussion
Previous studies have demonstrated that the HLA loci
are associated with IgAN in different populations but
not consistent with any alleles [1,15-20,24]. A family-
based and case–control association study using the
genome-wide association study (GWAS) approach sug-
gested that the HLA region contains the strongest
common susceptibility alleles of primary IgAN in a small
European cohort [25]. HLA Imputation Analysis shows
that the HLA-B, DRB1, DQA, and DQB loci are asso-
ciated with IgAN, and the strongest association was
observed at the HLA-DQ locus in the study [25].
Recently, a GWAS for primary IgAN identified three
independent loci in the major histocompatibility com-
plex in a cohort of 3,144 primary IgAN cases of Chinese
and European ancestry. The study showed that 27
SNPs exceeding genome-wide thresholds for significance
were located in a 0.54-Mb interval within the MHC.primary IgAN patients and healthy controls of
ntrols P OR 95% CI
3 (28) 2.35 × 10-3 1.541 1.130–2.100
3 (392) 2.67 × 10-3 1.091 1.028–1.158
2 (420) 8.29 × 10-5 1.381 1.178–1.619
Cochran-Mantel-Haenszel method; Tests of Homogeneity of the Odds Ratio:
Table 4 A comparison of the frequencies of HLA-DRB1*04
subtypes in primary IgAN patients and healthy controls




(n = 935× 2)
Controls
(n = 2088× 2)
P OR 95% CI
DRB1*0401 0.011 (21) 0.0010 (43) 0.786 1.028 0.866–1.221
DRB1*0402 0.003 (5) 0.002 (8) 0.556 1.123 0.730–1.726
DRB1*0403 0.029 (54) 0.014 (60) 2.088 × 10-4 1.318 1.107–1.570
DRB1*0404 0.005 (10) 0.007 (28) 0.601 0.937 0.774–1.134
DRB1*0405 0.067 (125) 0.037 (153) 5.225 × 10-7 1.267 1.138–1.411
DRB1*0406 0.026 (49) 0.021 (89) 0.263 1.073 0.947–1.215
DRB1*0407 0.004 (7) 0.002 (9) 0.284 1.229 0.797–1.893
DRB1*0408 0.002 (3) 0.002 (8) 1.000 0.950 0.661–1.364
DRB1*0409 0 0.009 (4) 0.318 - -
DRB1*0410 0.006 (11) 0.002 (9) 0.027 1.537 0.946–2.495
DRB1*0411 0.010 (3) 0 0.030 - -
DRB1*0419 0.001 (2) 0 0.096 0.416 0.381–0.455
DRB1*0420 0.0005(1) 0.0002(1) 0.523 1.382 0.345–5.525
OR, odds ratio; CI, confidence interval.
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strongest association was located within a ~170-kb inter-
val that includes HLA-DRB1, HLA-DQA1, and HLA-
DQB1 [26]. This further indicated that the HLA-DRB1
region is one of the major primary IgAN susceptibil-
ity loci.
The HLA-DRB1 locus is, by far, the most polymorphic
MHC class II locus and has more than 540 alleles [27].
Previous studies have found a significant association be-
tween IgAN and the HLA-DRB1 alleles in a Japanese
population [17,19,28]. Recently, a study showed that
HLA-DRB1 polymorphisms were related to the occur-
rence and disease progression of Han Chinese patientsTable 5 The association of HLA-DRB1*04 alleles with clinical a
HLA
Gender (n = 1104) Female 0.1
Male 0.1
SCr (umol/L) (n = 1079) ≤120 0.1
>120 0.1
Hematuria (n = 1061) No 0.1
Yes 0.1
Upro (g/24Hr) (n = 1056) ≤3.5 0.1
>3.5 0.1
Blood pressure (n = 1076) Normal 0.1
Hypertension 0.1
eGFR, ml/min/1.73 m2 (n = 1079) ≤60 0.1
>60 0.1
Glomeruloscerosis (n = 1079) No 0.1
Yes 0.1
OR, odds ratio; CI, confidence interval.with primary IgAN. HLA-DRB1*140501 was reported
to be a susceptible allele, and HLA-DRB1*070101 was
reported to be a resistant allele. HLA-DRB1*030101 may
serve as a predictor of disease progression and renal
damage of primary IgAN in Han Chinese [29]. However,
previous studies did not substantiate the conclusion
that HLA-DRB1 was significantly associated with IgAN
because a small number of samples were included in
these studies and there was no association between
the HLA-DR antigen and primary IgAN in Taiwanese
Chinese [20]. In our studies, all of these samples were
pre-typed at a low resolution using PCR –SSP, which
provided information on the HLA-DRB1 alleles at sero-
logical recognition. Then, we typed the HLA-DRB1*04
subtype alleles using a high resolution sequence-based
HLA-DRB1 typing of Exon 2. Compared with HLA-
DRB1 typing using the SBT approach for these samples,
it took less time and money to determine the allele
frequencies of HLA-DRB1 using a two-stage typing
approach combined with PCR-SSP and SBT. We further
confirmed that the genetic variants at the HLA-DRB1
gene were significantly associated with IgAN in a large
Han Chinese cohort composed of 1,127 cases and 2,295
controls. However, since our approach does not distin-
guish between the alleles DRB1*11 and *12, DRB1*13
and *14 and DRB1*15 and *16, it could be missing the
true associations between other HLA-DRB1 alleles as
well. In addition, the IgAN GWAS study demonstrated a
strong protective effect of the DRB1*15 allele (OR=0.61,
P=10-6) and potentially of other DRB1 alleles [26].
As for diseases of polygenic inheritance, there are differ-
ent disease susceptibility genes in different populations.
Primary IgAN, defined as predominant IgA mesangial
deposits in the absence of clinical or laboratory evidencend pathological parameters of primary IgAN patients
-DRB1*04 P OR 95% CI
33 (143) 0.850 1.015 0.809-1.146
30 (157)
36 (229) 0.705 1.051 0.830-1.331
29 (62)
25 (19) 0.806 0.994 0.961–1.028
35 (266)
38 (233) 0.875 1.025 0.798–1.316
34 (57)
43 (171) 0.228 1.095 0.946–1.267
25 (120)
30 (241) 0.784 0.964 0.711–1.307
35 (41)
24 (201) 0.120 0.844 0.691–1.032
51 (81)
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posed to include at least two distinct clinical entities
(those with and without macroscopic hematuria) [1,30,31],
which may be determined by different susceptibility
genes. Therefore, heterogeneity between populations
may account for some of the controversy in HLA asso-
ciations with IgAN.
The allelic frequency and diversity of HLA-DRB1
among different populations emphasizes the need for re-
search using matched patient and control groups in gen-
etic association studies. Some reports indicate that the
population of Metropolitan Beijing, in the northern part
of China, includes a mixture of individuals from both
the northern and central provinces. However, these
reports have also found that there are few people from
the southern region[32]. In addition, the reports indicate
that the population mix of the Sichuan province, consid-
ered representative of southern China, could in fact have
been affected by the mass migrations during the late
Ming and early Qing dynasties. At those times, people
came to Sichuan from both the southern and the central
regions, such as Hunan and Hubei[32]. As a result, the
cases and controls for our studies have been recruited
through geographic matching, to eliminate the adverse
impact of stratification. We evaluated the allelic fre-
quency of HLA-DRB1 in the Sichuan cohort (192 cases
and 192 controls) and the Beijing cohort (935 cases and
2,103 controls). Subsequently, we analyzed the Sichuan
and Beijing cohorts together and confirmed a strong
association with primary IgAN susceptibility, that the
allele frequency of HLA-DRB1*04 was significantly asso-
ciated with primary IgAN susceptibility. HLA-DRB1*0405
and 0403 were the susceptible allele of pIgAN patients
in Han Chinese population. However, there is no signifi-
cant association between clinical factors and the fre-
quency of the HLA-DRB1*04 alleles and its subtype in
primary IgAN patients.
In summary, this study showed that the HLA-DRB1*04
had a strong association with primary IgAN in a Chinese
population. In our disease association studies, all of these
samples were pre-typed at a low resolution using PCR
–SSP, which may limit our ability to detect rare alleles of
HLA DRB1. The primary technology used to detect rare
alleles of HLA-DRB1 is the high resolution SBT, which
could contribute to the proper identification of suscep-
tible or resistant alleles of IgAN. HLA-DRB1 has been
shown to be associated with many autoimmune diseases,
however, the mechanism of the HLA-DRB1 causing IgAN
is poorly understood. Thus further research exploring the
pathogenesis of HLA-DRB1 with IgAN is needed.
Conclusion
HLA-DRB1*04 was significantly associated with primary
IgAN in Chinese population. HLA-DRB1*0405 and 0403were the susceptible allele of pIgAN patients in Han
Chinese population. However, there is no significant
association between clinical factors and the frequency of
the HLA-DRB1*04 alleles and its subtype in primary
IgAN patients.
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